Sidley Austin represented Roche in the transaction, and Cooley represented Poseida Therapeutics. Roche, one of the world’s largest biotechnology companies and the global leader in in-vitro...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Cooley advised Kura Oncology. Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...
You must be a Standard 1 Year member to access this content.
Cooley advised SystImmune on the transaction. SystImmune announced its exclusive license and collaboration agreement with Bristol Myers Squibb (NYSE: BMY) for SystImmune’s BL-B01D1. Under the terms of...
You must be a Standard 1 Year member to access this content.
Cooley advised Definitive Healthcare on the deal. Definitive Healthcare (Nasdaq: DH) announced its acquisition of Populi for $52 million in an all-cash transaction. This acquisition furthers Definitive...
You must be a Standard 1 Year member to access this content.
Cooley is acting as legal counsel to Veritone, and Sidley Austin is acting as legal counsel to Career Builder. Veritone, Inc. (NASDAQ: VERI) announced its agreement...
You must be a Standard 1 Year member to access this content.
Cooley advised Angion on the deal. Angion, a clinical-stage biopharmaceutical company, announced its definitive merger agreement with Elicio Therapeutics. Elicio will merge with a wholly owned subsidiary...
You must be a Standard 1 Year member to access this content.
Cooley advised Tmunity on the deal. Tmunity, a clinical-stage biotechnology company, announced its agreement to sell to Kite, a global biopharmaceutical company. The acquisition will provide...
You must be a Standard 1 Year member to access this content.
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
You must be a Standard 1 Year member to access this content.
Skadden advised Vertex Pharmaceuticals Incorporated on the deal while Cooley represented ViaCyte. Vertex Pharmaceuticals Incorporated (“Vertex”) has entered into a definitive agreement under which Vertex will acquire...
You must be a Standard 1 Year member to access this content.
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
You must be a Standard 1 Year member to access this content.
Cooley advised Biote on the deal. Biote, a medical practice-building business within the hormone optimization space, announced its definitive business combination agreement with special purpose acquisition company...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Prodege on the deal. Prodege, a cutting-edge marketing and consumer insights platform, announced its definitive agreement to secure a major investment from private equity...
You must be a Standard 1 Year member to access this content.
